AI-generated summary
The authors reviewed randomized trials of second-generation antidepressants for preventing seasonal affective disorder in adults with a history of the condition. Three trials with 1100 participants met criteria, and the authors report that bupropion XL was associated with fewer recurrent depressive episodes than placebo, though it increased headaches, insomnia and nausea. The trials had high attrition, and no studies of other antidepressants or non-drug comparisons were found.
- Participants
- 1,100
- Studies included
- 3
- Who or what was studied
- Adults with a history of winter-type seasonal affective disorder who were free of symptoms at study start
- Limits stated in the abstract
- All three included trials had methodological limitations due to high attrition rates, and no studies of other antidepressants or non-drug comparators were found.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on doi.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Heterogeneity, Risk of bias, Publication bias, Confidence interval, Depression, Attrition, Insomnia, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.